Dexcom Inc (DXCM) 62.68 $DXCM
DexCom Shares Up 45.7% Since SmarTrend's Buy Recommendation (DXCM)
Comtex SmarTrend(R) - Thu Feb 12, 9:53AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 4 months, DexCom has returned 45.65% as of today's recent price of $63.09.
DXCM: 62.68 (+0.74)
3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 11:01AM CST
2015 is forecasted to be a transition year for the medical instruments sector.
GNMK: 13.51 (+0.21), DXCM: 62.68 (+0.74), TNDM: 13.16 (+0.25)
Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:00AM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10.
ACAD: 34.21 (+0.37), ACT: 285.37 (+3.71), DXCM: 62.68 (+0.74), CVS: 102.63 (-0.37)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Uptrend Call Working As DexCom Stock Rises 41.5% (DXCM)
Comtex SmarTrend(R) - Thu Feb 05, 9:09AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ XCM) on October 21st, 2014 at $43.32. In approximately 4 months, DexCom has returned 41.45% as of today's recent price of $61.27.
DXCM: 62.68 (+0.74)
Oil Is In Recovery Mode - Cramer's Mad Money (2/2/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 03, 6:25AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 2. Is January's miserable pattern over? Is there a new pattern emerging in February? Cramer looked back at January and said it had an asymmetrical...
F: 16.30 (-0.06), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), FB: 75.74 (-0.49), HAL: 44.19 (+1.42), BBY: 39.11 (-0.08), SNE: 27.30 (+0.19), XOM: 93.37 (+1.00), CVRR: 20.20 (+0.58), CLB: 112.18 (+3.65), SLB: 88.38 (+2.42), MSF: 15.08 (+0.06), DXCM: 62.68 (+0.74), CVX: 112.78 (+1.92), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: FB AAPL HAR URI DXCM
at The Street - Tue Feb 03, 5:00AM CST
Cramer says Harman is in the driver's seat and DexCom is an innovative medical-device company.
HAR: 136.40 (-3.18), DXCM: 62.68 (+0.74), FB: 75.74 (-0.49), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
Jim Cramer's 'Mad Money' Recap: New Month, New Rally in the Making?
at The Street - Mon Feb 02, 7:27PM CST
The markets were able to do something remarkable -- breaking the cycle of pain and ending the day higher after a weak open, Cramer says.
SCCO: 30.43 (+0.30), AMZN: 381.83 (+4.66), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), ATLS: 30.17 (+0.27), FB: 75.74 (-0.49), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86), WHR: 213.23 (+0.18), DXCM: 62.68 (+0.74), QCOM: 70.88 (+0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
DexCom to Present at 4th Annual Leerink Partners Global Healthcare Conference
Business Wire - Thu Jan 29, 7:30AM CST
DexCom, Inc. (NASDAQ XCM) today announced that Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present an update on the company at the 4th Annual Leerink Partners Global Healthcare Conference in New York, New York on Wednesday, February 11, 2015 at 8:50am (EST). The presentation, which will occur live at the Waldorf Astoria, will be concurrently webcast.
DXCM: 62.68 (+0.74)
Shares of DXCM Up 39.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 28, 4:38PM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ XCM) on October 21st, 2014 at $43.32. In approximately 3 months, DexCom has returned 39.88% as of today's recent price of $60.59.
DXCM: 62.68 (+0.74)
FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 3:35PM CST
Developer of continuous glucose monitoring systems, DexCom, Inc. (DXCM), recently received the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share.
DXCM: 62.68 (+0.74), INGN: 33.53 (+2.32), AAPL: 127.08 (+0.62), SURG: 4.44 (-0.02)
Dexcom's Smart Glucose Monitoring System Receives FDA Approval
TipRanks - Seeking Alpha - Wed Jan 28, 1:38PM CST
By Sarah Roden Dexcom's (NASDAQ: DXCM ) G4 Platinum Continuous Glucose Monitoring System received FDA approval yesterday on January 27th. Dexcom develops monitors that detect glucose levels to help manage diabetes. The new device utilizes...
DXCM: 62.68 (+0.74)
DexCom: More Good News For Diabetes Patients And Shareholders
Bill Gunderson - Seeking Alpha - Tue Jan 27, 1:16PM CST
DexCom (NASDAQ: DXCM ) stock is trading up on news that its medical app system, the DexCom Share system, to be used in conjunction with its G4 Platinum Continuous Glucose Monitoring device, received FDA approval . San Diego-based DexCom, besides...
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), DXCM: 62.68 (+0.74), MDT: 75.26 (+0.33)
DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 8:25AM CST
DexCom (DXCM) was a big mover last session, with its shares rising over 8% on the day.
ABMD: 60.39 (+0.46), DXCM: 62.68 (+0.74)
FDA clears DexCom glucose monitoring system receiver
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 8:23AM CST
DXCM: 62.68 (+0.74)
FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
Business Wire - Mon Jan 26, 7:01AM CST
DexCom, Inc., (NASDAQ XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and an app on the patient's smartphone to transmit glucose information to apps on the mobile devices of up to five designated recipients, or "followers," without the need for a dedicated docking cradle. These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere, initially via their Apple(R) iPhone(R) or iPod(R) touch and in the future on Android devices, giving them peace of mind and reassurance when they are apart. The "Share" and "Follower" apps will be available on the Apple App Store at no charge.
DXCM: 62.68 (+0.74)
Dexcom OK to market glucose monitoring app
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 3:16PM CST
DXCM: 62.68 (+0.74)
DexCom Shares Up 33.4% Since SmarTrend's Buy Recommendation (DXCM)
Comtex SmarTrend(R) - Wed Jan 21, 11:00AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ XCM) on October 21st, 2014 at $43.32. In approximately 3 months, DexCom has returned 33.39% as of today's recent price of $57.78.
DXCM: 62.68 (+0.74)
Health Care Equipment Equities Technical Notes - CareFusion, Baxter Intl., Becton Dickinson, DexCom, and Thoratec
PR Newswire - Thu Jan 15, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: CareFusion Corporation (NYSE: CFN), Baxter International Inc. (NYSE: BAX), Becton Dickinson and Company (NYSE: BDX), DexCom Inc. (NASDAQ: DXCM), and Thoratec Corporation (NASDAQ: THOR). Free research reports can be accessed at: http://investor-edge.com/register. On Wednesday, January 14, 2015, the NASDAQ Composite ended at 4,639.32, down 0.48%, the Dow Jones Industrial Average declined 1.06%, to finish the day at 17,427.09, and the S&P 500 closed at 2,011.27, down 0.58%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 807.94, down 0.10%, while the index has advanced 14.47% in the previous three months. Register for your complimentary reports at:
BDX: 143.71 (+0.72), DXCM: 62.68 (+0.74), BAX: 70.39 (+0.31), CFN: 59.81 (+0.01), THOR: 40.01 (+0.54)
DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:45PM CST
Developer of continuous glucose monitoring systems, DexCom Inc. (DXCM), recently announced preliminary product revenues for fourth quarter and full year 2014
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), DXCM: 62.68 (+0.74), MDT: 75.26 (+0.33)
DexCom Shares Up 45.7% Since SmarTrend's Buy Recommendation (DXCM)
Comtex SmarTrend(R) - Thu Feb 12, 9:53AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 4 months, DexCom has returned 45.65% as of today's recent price of $63.09. DXCM: 62.68 (+0.74)
3 Med-Instrument Stocks Poised to Gain this Earnings Season - Earnings ESP
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 11:01AM CST
2015 is forecasted to be a transition year for the medical instruments sector.
GNMK: 13.51 (+0.21), DXCM: 62.68 (+0.74), TNDM: 13.16 (+0.25)
Will CVS Health's (CVS) Earnings Surprise this Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 10:00AM CST
CVS Health Corporation (CVS) ??? formerly known as CVS Caremark ??? is scheduled to report its fourth-quarter and full year 2014 results before the opening bell on Feb 10.
ACAD: 34.21 (+0.37), ACT: 285.37 (+3.71), DXCM: 62.68 (+0.74), CVS: 102.63 (-0.37)
Miraculins Moves Closer to Commercialization
ACCESSWIRE - Mon Feb 09, 7:01AM CST
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
PODD: 32.00 (-0.07), DXCM: 62.68 (+0.74), NVO: 43.76 (+0.61), MOM.VN: 0.210 (+0.005), LLY: 70.56 (+0.03)
Uptrend Call Working As DexCom Stock Rises 41.5% (DXCM)
Comtex SmarTrend(R) - Thu Feb 05, 9:09AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 4 months, DexCom has returned 41.45% as of today's recent price of $61.27. DXCM: 62.68 (+0.74)
Oil Is In Recovery Mode - Cramer's Mad Money (2/2/15)
SA Editor Mohit Manghnani - Seeking Alpha - Tue Feb 03, 6:25AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday, February 2. Is January's miserable pattern over? Is there a new pattern emerging in February? Cramer looked back at January and said it had an asymmetrical...
F: 16.30 (-0.06), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), FB: 75.74 (-0.49), HAL: 44.19 (+1.42), BBY: 39.11 (-0.08), SNE: 27.30 (+0.19), XOM: 93.37 (+1.00), CVRR: 20.20 (+0.58), CLB: 112.18 (+3.65), SLB: 88.38 (+2.42), MSF: 15.08 (+0.06), DXCM: 62.68 (+0.74), CVX: 112.78 (+1.92), URI: 92.98 (+1.41)
Jim Cramer's Top Stock Picks: FB AAPL HAR URI DXCM
at The Street - Tue Feb 03, 5:00AM CST
Cramer says Harman is in the driver's seat and DexCom is an innovative medical-device company.
HAR: 136.40 (-3.18), DXCM: 62.68 (+0.74), FB: 75.74 (-0.49), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
Jim Cramer's 'Mad Money' Recap: New Month, New Rally in the Making?
at The Street - Mon Feb 02, 7:27PM CST
The markets were able to do something remarkable -- breaking the cycle of pain and ending the day higher after a weak open, Cramer says.
SCCO: 30.43 (+0.30), AMZN: 381.83 (+4.66), HAR: 136.40 (-3.18), AXP: 78.08 (-2.40), ATLS: 30.17 (+0.27), FB: 75.74 (-0.49), IP: 57.31 (+0.12), ILMN: 198.54 (+1.81), PKG: 82.89 (+1.86), WHR: 213.23 (+0.18), DXCM: 62.68 (+0.74), QCOM: 70.88 (+0.49), MSFT: 43.87 (+0.78), AAPL: 127.08 (+0.62), URI: 92.98 (+1.41)
DexCom to Present at 4th Annual Leerink Partners Global Healthcare Conference
Business Wire - Thu Jan 29, 7:30AM CST
DexCom, Inc. (NASDAQ
XCM) today announced that Steve Pacelli, Executive Vice President of Strategy and Corporate Development, will present an update on the company at the 4th Annual Leerink Partners Global Healthcare Conference in New York, New York on Wednesday, February 11, 2015 at 8:50am (EST). The presentation, which will occur live at the Waldorf Astoria, will be concurrently webcast. DXCM: 62.68 (+0.74)
Shares of DXCM Up 39.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jan 28, 4:38PM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 3 months, DexCom has returned 39.88% as of today's recent price of $60.59. DXCM: 62.68 (+0.74)
FDA OKs DexCom Glucose Monitoring System with Share App - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 3:35PM CST
Developer of continuous glucose monitoring systems, DexCom, Inc. (DXCM), recently received the FDA approval for its Dexcom G4 PLATINUM Continuous Glucose Monitoring System with Share.
DXCM: 62.68 (+0.74), INGN: 33.53 (+2.32), AAPL: 127.08 (+0.62), SURG: 4.44 (-0.02)
Dexcom's Smart Glucose Monitoring System Receives FDA Approval
TipRanks - Seeking Alpha - Wed Jan 28, 1:38PM CST
By Sarah Roden Dexcom's (NASDAQ: DXCM ) G4 Platinum Continuous Glucose Monitoring System received FDA approval yesterday on January 27th. Dexcom develops monitors that detect glucose levels to help manage diabetes. The new device utilizes...
DXCM: 62.68 (+0.74)
DexCom: More Good News For Diabetes Patients And Shareholders
Bill Gunderson - Seeking Alpha - Tue Jan 27, 1:16PM CST
DexCom (NASDAQ: DXCM ) stock is trading up on news that its medical app system, the DexCom Share system, to be used in conjunction with its G4 Platinum Continuous Glucose Monitoring device, received FDA approval . San Diego-based DexCom, besides...
JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), DXCM: 62.68 (+0.74), MDT: 75.26 (+0.33)
DexCom (DXCM) Worth Watching: Stock Moves 8.4% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 27, 8:25AM CST
DexCom (DXCM) was a big mover last session, with its shares rising over 8% on the day.
ABMD: 60.39 (+0.46), DXCM: 62.68 (+0.74)
FDA clears DexCom glucose monitoring system receiver
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 8:23AM CST
DXCM: 62.68 (+0.74)
FDA Approves Dexcom G4 Platinum Continuous Glucose Monitoring System with Share
Business Wire - Mon Jan 26, 7:01AM CST
DexCom, Inc., (NASDAQ
XCM), a leader in continuous glucose monitoring (CGM) for patients with diabetes, announced today that it has received U.S. Food and Drug Administration (FDA) approval for its Dexcom G4(R) PLATINUM Continuous Glucose Monitoring System with Share. The Dexcom Share receiver uses a secure wireless connection via Bluetooth Low Energy (BLE) between a patient's receiver and an app on the patient's smartphone to transmit glucose information to apps on the mobile devices of up to five designated recipients, or "followers," without the need for a dedicated docking cradle. These followers can remotely monitor a patient's glucose information and receive alert notifications from almost anywhere, initially via their Apple(R) iPhone(R) or iPod(R) touch and in the future on Android devices, giving them peace of mind and reassurance when they are apart. The "Share" and "Follower" apps will be available on the Apple App Store at no charge. DXCM: 62.68 (+0.74)
Dexcom OK to market glucose monitoring app
Seeking Alpha - at Seeking Alpha - Fri Jan 23, 3:16PM CST
DXCM: 62.68 (+0.74)
DexCom Shares Up 33.4% Since SmarTrend's Buy Recommendation (DXCM)
Comtex SmarTrend(R) - Wed Jan 21, 11:00AM CST
SmarTrend identified an Uptrend for DexCom (NASDAQ
XCM) on October 21st, 2014 at $43.32. In approximately 3 months, DexCom has returned 33.39% as of today's recent price of $57.78. DXCM: 62.68 (+0.74)
Health Care Equipment Equities Technical Notes - CareFusion, Baxter Intl., Becton Dickinson, DexCom, and Thoratec
PR Newswire - Thu Jan 15, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: CareFusion Corporation (NYSE: CFN), Baxter International Inc. (NYSE: BAX), Becton Dickinson and Company (NYSE: BDX), DexCom Inc. (NASDAQ: DXCM), and Thoratec Corporation (NASDAQ: THOR). Free research reports can be accessed at: http://investor-edge.com/register. On Wednesday, January 14, 2015, the NASDAQ Composite ended at 4,639.32, down 0.48%, the Dow Jones Industrial Average declined 1.06%, to finish the day at 17,427.09, and the S&P 500 closed at 2,011.27, down 0.58%. The losses were broad based as eight out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 807.94, down 0.10%, while the index has advanced 14.47% in the previous three months. Register for your complimentary reports at:
BDX: 143.71 (+0.72), DXCM: 62.68 (+0.74), BAX: 70.39 (+0.31), CFN: 59.81 (+0.01), THOR: 40.01 (+0.54)
DexCom Declares Preliminary Q4 '14 Revenues, Guides '15 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 14, 4:45PM CST
Developer of continuous glucose monitoring systems, DexCom Inc. (DXCM), recently announced preliminary product revenues for fourth quarter and full year 2014
ABT: 46.09 (+0.87), JNJ: 99.62 (+1.18), DXCM: 62.68 (+0.74), MDT: 75.26 (+0.33)
